Evaluating Alcoholism as the Cause of Abnormal LFTs and Blood Cell Counts

Laboratory Patterns Suggestive of Alcoholic Liver Disease

The American Association for the Study of Liver Diseases recommends that an AST/ALT ratio >2 is highly suggestive of alcoholic liver disease, with ratios >3 being even more specific 1, 2
AST is typically elevated 2-6 times the upper limit of normal in alcoholic hepatitis, according to the American Association for the Study of Liver Diseases 1
The European Association for the Study of the Liver states that AST levels >500 IU/L or ALT >200 IU/L are uncommon in alcoholic liver disease and suggest alternative etiologies 1, 2
Elevated GGT is common but has limited sensitivity and specificity when used alone, as noted by the American Association for the Study of Liver Diseases 1, 3
The mean corpuscular volume (MCV) is often elevated in chronic alcohol use, as reported by the European Association for the Study of the Liver 4, 5
The combination of raised GGT and elevated MCV improves sensitivity for diagnosing alcohol abuse, according to the American Association for the Study of Liver Diseases 1
Thrombocytopenia may be present in advanced alcoholic liver disease, as stated by the European Association for the Study of the Liver 4

The World Health Organization recommends the AUDIT (Alcohol Use Disorders Identification Test) questionnaire with a score ≥8 for men up to age 60 or ≥4 for women, adolescents, or men over 60 considered positive 1
The CAGE questionnaire is widely used due to its simplicity, as noted by the American Medical Association 6
Combining questionnaires with laboratory markers improves diagnostic accuracy, according to the European Association for the Study of the Liver 4

The American Association for Clinical Chemistry states that ethyl glucuronide (EtG) in urine can detect alcohol use for up to 3-4 days after consumption 7
Hair EtG (hEtG) can detect chronic excessive alcohol consumption with high sensitivity and specificity, as reported by the European Association for the Study of the Liver 7
The Society of Hair Testing notes that internationally accepted cut-off values for hEtG are: <7 pg/mg (abstinence), 7-30 pg/mg (social drinking), >30 pg/mg (chronic excessive consumption) 7

The American Association for the Study of Liver Diseases recommends screening for alcohol use disorder using the AUDIT questionnaire (positive if score ≥8 for men up to age 60, or ≥4 for women, adolescents, or men over 60) 1
The European Association for the Study of the Liver suggests evaluating laboratory patterns, including AST/ALT ratio (>2 suggests alcoholic etiology) 1, 2
The American Association for the Study of Liver Diseases recommends assessing GGT and MCV (both elevated in chronic alcohol use) 1, 4
The European Association for the Study of the Liver advises testing for viral hepatitis (HBV, HCV) 4
The American Association for the Study of Liver Diseases recommends considering liver biopsy if diagnosis remains uncertain or competing etiologies are suspected 4, 8

The American Association for the Study of Liver Diseases notes that normal LFTs do not exclude significant alcohol-related liver disease 3
The European Association for the Study of the Liver states that up to 20% of patients with alcohol use disorder and abnormal LFTs have coexisting liver disease etiologies 5, 8
The American Association for Clinical Chemistry advises that GGT loses specificity for alcohol in advanced liver disease 3
The European Association for the Study of the Liver notes that AST/ALT ratio becomes less specific in the cirrhotic stage 3
The American Association for the Study of Liver Diseases recommends that liver biopsy remains the gold standard for definitive diagnosis but carries risks and is not required in all cases 4, 8

The American Association for the Study of Liver Diseases recommends that abstinence is the most effective intervention to reduce liver enzyme abnormalities and prevent disease progression 3

The European Association for the Study of the Liver recommends using non-invasive assessment with FibroScan® or specialized blood tests (FibroTest® or FibroMeter Alcohol®) as first-line evaluation for fibrosis staging in all patients with suspected alcoholic liver disease, while avoiding reliance on transaminases alone for screening 9
Documenting alcohol consumption history is crucial, with daily intake of more than 30 grams per day suggesting risk for alcoholic liver disease, and the pattern of drinking should also be quantified 10
Physical findings such as bilateral parotid gland hypertrophy, muscle wasting, malnutrition, Dupuytren's contracture, and symmetric peripheral neuropathy should be assessed in patients with suspected alcoholic liver disease 10

The American Association for the Study of Liver Diseases recommends performing FibroScan® (transient elastography) or specialized blood tests (FibroTest® or FibroMeter Alcohol®) in all patients with suspected alcoholic liver disease, as these methods detect advanced fibrosis/cirrhosis with approximately 95% accuracy 9
The APRI score is not recommended for fibrosis assessment in alcoholic liver disease 9

Liver biopsy should be reserved for specific clinical scenarios, such as suspected alcoholic hepatitis requiring specific treatment, discordant non-invasive test results, suspected coexisting chronic liver disease, or atypical presentation with confounding factors 9
The transjugular approach should be used for liver biopsy in patients with coagulopathy, thrombocytopenia, or ascites 11, 12

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) classification system should be applied when alcoholic hepatitis is suspected, with definite, probable, and possible categories based on clinical diagnosis and biopsy results 11, 13, 12
The Maddrey Discriminant Function and MELD score should be calculated to identify severe forms of alcoholic hepatitis, with a Maddrey score of 32 or higher defining severe disease 13, 12

Screening for cognitive impairment, metabolic syndrome, and smoking status is recommended in patients with alcoholic liver disease, as these factors can impact disease progression and management 14, 9